Executive Management Team
Charles H. Sherwood, Ph.D. has been Chief Executive Officer of Anika Therapeutics since 2002. From 2002 through July 2017, he also held the title of President. Dr. Sherwood joined Anika in 1998 with extensive experience in research, engineering, manufacturing, quality assurance, regulatory affairs and business management. He first served at Anika in the position of Vice President of Research, Development and Engineering.
Prior to joining Anika, he was a senior director with Chiron Vision, responsible for medical product development and commercialization. From 1982 to 1995, Dr. Sherwood was with IOLAB Corporation, a division of Johnson & Johnson, where he led the Research and Product Development organization. Earlier, he held various technical and management positions with Hughes Aircraft Company and Lord Corporation. He was also on the faculty of California State Polytechnic University, Pomona.
Dr. Sherwood holds a doctorate and master's degree in polymer science and engineering from the University of Massachusetts, a bachelor's degree in chemical engineering from Cornell University and a certificate in management from Claremont Graduate School.
Joseph Darling joined Anika Therapeutics, Inc. as the company’s President on July 27, 2017. Joseph brings with him substantial executive leadership and commercial experience based on a long career in the pharmaceutical and medical device industries. Most recently, Joseph held executive leadership positions at two small, privately-held companies. Prior to these roles, Joseph held senior level executive positions at ConMed Corporation, a global, publicly-held, diversified medical device company, as Global President of its wholly-owned subsidiary, Linvatec Corporation, and as Executive Vice President of Global Corporate Commercial Operations. In these roles, Joesph was responsible for the overall strategic worldwide operations of ConMed’s orthopedic business. He has also served in executive and leadership roles with Smith & Nephew and Baxter Healthcare. Joseph launched his career in the life sciences field at Wyeth-Ayerst Pharmaceuticals and Abbott Laboratories where he held management positions in sales and marketing.
Joseph holds a B.A. in Political Science from Syracuse University.
On April 1, 2013 Sylvia Cheung was appointed as Chief Financial Officer. Ms. Cheung brings to Anika a substantial number of years of financial and general management experience. Prior to her current position, Sylvia was the Vice President of Strategic Processes; and previously, she served as the General Manager for the company's Italian-based subsidiary, Anika S.r.l. She joined Anika as Controller in 2005. In addition to fulfilling wide-ranging financial responsibilities as Controller, Sylvia led the company's integration of Anika S.r.l. subsequent to its acquisition in 2009.
Prior to Anika, she held a series of progressively responsible financial management positions at Transkaryotic Therapies, Inc. From 1995 to 2000, Sylvia worked for PricewaterhouseCoopers, LLP as an Audit Senior Associate.
Sylvia holds a bachelor of business administration degree in accounting from the University of Massachusetts in Amherst, a master's degree in business administration from Boston University, and is a Certified Public Accountant (inactive).
Richard Hague joined Anika Therapeutics, Inc. as Chief Commercial Officer on October 26, 2015. Most recently, Richard served as Vice President, Sales and Marketing, for TEI Medical, where he was responsible for driving revenue growth, building the sales and marketing teams, and implementing strategies to drive national account and federal and private payer acceptance of the company’s technology platform. He previously was Vice President, Sales, Marketing and Commercial Operations at Sanofi Biosurgery, where he led the build out of the global sales and marketing team and oversaw all commercial activities in the U.S. for the company’s Cell Therapy and Regenerative Medicine business. Richard’s prior experience also includes leadership positions at Genzyme Biosurgery as Senior Director and Head of U.S. Sales, and Northeast Regional Sales Director.
Richard holds a B.S. in Marketing from the University of Connecticut.
Dana Alexander joined Anika Therapeutics, Inc. as its Chief Operations Officer on April 4, 2016. Prior to joining Anika, Dana spent the previous 14 years in various leadership roles at Genzyme Corporation. Most recently, Mr. Alexander served as Senior Director of Biologics Manufacturing Operations, where he headed manufacturing at Genzyme’s flagship biologics plant including overseeing production planning and execution, bringing new manufacturing capacity on-line, and implementing new production and quality systems. During his tenure at Genzyme, Mr. Alexander provided operational oversight for the construction, start-up, and approval of a new cGMP cell culture facility, managed Chemistry, Manufacturing, and Control (CMC) activities for a variety of late stage and commercial products, and led operation product teams across complex supply chains to deliver global clinical and commercial supply requirements.
Dana holds a Master's in Business Administration from Boston University, and a Bachelor of Science in Chemical Engineering from Northeastern University.
Edward Ahn, Ph.D., joined Anika Therapeutics, Inc. as Chief Technology and Strategy Officer on October 30, 2014. Most recently, Dr. Ahn was Managing Director and Chief Science Officer at MedCap Advisors where he built merger strategies, strategic partnerships and licensing agreements for emerging medical device, biotechnology and biological organizations with a focus on regenerative medicine. Prior to his work at MedCap, Dr. Ahn was Vice President of Product Development for Pioneer Surgical Biologics. In this role Dr. Ahn directed Pioneer Surgical Biologic's product development policies, objectives and initiatives. He has also served as Chief Executive Officer, Chief Technology Officer and Founder of Angstrom Medica, Inc., a company based upon his doctoral thesis work and focused on commercializing nanotechnology in the area of Orthopedics.
Dr. Ahn holds a B.S. in Chemical Engineering from Stanford University and M.S. (Chemical Engineering Practice) and Ph.D. in Chemical Engineering from Massachusetts Institute of Technology.
Steven Chartier joined Anika Therapeutics, Inc. as the Company’s Vice President of Regulatory and Clinical Affairs on August 28, 2017. Most recently, Steven was Vice President of Regulatory Affairs and Quality Assurance at Augmenix Inc. where he was responsible for all Regulatory and Quality functions and activities within the organization. Prior to his work at Augmenix, Steven was the Chief Operations Officer and a member of the executive management team at Pixarbio Corporation where he oversaw the development of and led all Regulatory, Quality, and Clinical programs for the organization. Steven has also held senior leadership roles at a number of other Medical Device, Life Sciences, and Pharmaceutical organizations including Infraredx, Inc., Nucryst Pharmaceuticals, Inc., and Biogen, Inc. Steven launched his career in clinical research at the Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center.
Steven holds a B.A. in Psychology from Saint Anselm College and has maintained a Regulatory Affairs Certification (RAC) since 2003.
On March 24, 2014, Steven Cyr joined Anika Therapeutics Inc. as the Vice President of Human Resources. He is responsible for all of the global human capital activities and programs of the company. Steve comes to Anika from DENTSPLY International, formerly Astra Tech Inc.(Astra Zeneca) in Waltham, MA where he worked from 2006 to 2014. Steve served as Vice President, Human Resources DENTSPLY Implants Division (North America). He was responsible for leading and managing all aspects of HR for the Dental Implant and Urology divisions. The employee population included sales, marketing, operations, R&D, manufacturing, and G&A. Previously, Steve was employed by Sepracor Pharmaceuticals in Marlborough, MA as the Associate Director Human Resources, Client Services. In addition, he has worked as a consultant supporting HR initiatives at Monster Worldwide in Maynard and DePuy AcroMed Medical Devices in Raynham. Furthermore, he has held positions with StorageNetworks, Inc., The Avicon Group, Inc., i2 Technologies, Cambridge Technology Partners, TASC, and Wang Information Services Corp.
Steve has a B.S. from the University of Maine in Liberal Arts Psychology (Honors), and an M.A. in Industrial /Organizational Psychology (Honors) from the University of New Haven.
Ellen MacKenzie joined Anika Therapeutics, Inc. as Vice President of Finance and Corporate Controller on September 26, 2016. Most recently, Ms. MacKenzie worked as a consultant for CFGI, a specialized financial consulting firm where she provided financial leadership to companies experiencing a range of routine and complex business scenarios. Prior to her work at CFGI, Ms. MacKenzie was the Senior Director and Controller for Benchmark Senior Living where she streamlined their financial reporting processes and restructured, developed, and managed a large team of accountants performing with a broad range of responsibilities including acquisition and strategic initiatives. Before that she held CFO and Corporate Controller positions at organizations including Catalyst Health Ventures and Bain Willard Companies, LP. Ms. MacKenzie began her career in public accounting with Price Waterhouse and Ernst & Young, LLP.
Ellen holds a B.S. in Accounting from Merrimack College, where she graduated Summa Cum Laude, and she is a Certified Public Account (inactive).